Self-bound Bose mixtures

Recent experiments confirmed that fluctuations beyond the mean-field approximation can lead to self-bound liquid droplets of ultra-dilute binary Bose mixtures. We proceed beyond the beyond-mean-field approximation, and study liquid Bose mixtures using the variational hypernetted-chain Euler Lagrange method, which accounts for correlations non-perturbatively. Focusing on the case of a mixture of uniform density, as realized inside large saturated droplets, we study the conditions for stability against evaporation of one of the components (both chemical potentials need to be negative) and against liquid-gas phase separation (spinodal instability), the latter being accompanied by a vanishing speed of sound. Dilute Bose mixtures are stable only in a narrow range near an optimal ratio $\rho_1/\rho_2$ and near the total energy minimum. Deviations from a universal dependence on the s-wave scattering lengths are significant despite the low density.Comment: 5 pages, 5 figure

Identifying New England’s underutilized seafood species and evaluating their market potential in a changing climate

Developing and diversifying market opportunities for lesser known yet abundant seafood species has been a successful strategy for seafood businesses in the Northeast United States. Since climate change and other stressors are currently threatening the economic vitality of New England’s seafood industry, it is important to identify if there are lesser-known species that could simultaneously support additional market opportunities and remain resilient in a warming climate. We developed a quantitative definition for the term “underutilized species’’ based on five criteria derived from science-based sustainable fishing metrics. Using this definition, we evaluated 47 stocks in the Northeast United States during the initial time period of 2013-2017 to identify seven underutilized finfish species that could be considered for new market opportunities as part of a climate-smart approach: 1) Acadian redfish (Sebastes fasciatus), 2) Atlantic pollock (Pollachius virens), 3) butterfish (Peprilus triacanthus), 4) haddock (Melanogrammus aeglefinus), 5) scup (Stenotomus chrysops), 6) silver hake (Merluccius bilinearis), and 7) white hake (Urophycis tenuis). The climate resiliency of these resulting seven species was then evaluated using a framework consisting of species-specific metrics on climate sensitivity, directionality (of responses to climate impacts) and future habitat availability under warming scenarios. Our results show that assessing underutilized species on a regular basis and evaluating their ongoing responses to climate change can be a part of a climate-smart approach towards building more diversified and adaptive markets

Nanotechnology and azo-dyes in sweets

Nanotechnology is a fast growing field and consider as a key-technology of the 21st century. Nanoparticles are not only used in high-tech products or medical devices but are also more and more incorporated in food producers, for example in sweets. In addition, for food-coloring, azo-dyes are frequently used which makes an encounter of azo-dyes and nanoparticles unavoidable, The aim of this work was the isolation and characterisation of these dyes without including nanoparticles in a selected sweet product

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials

Background: The clinical efficacy and safety of a mometasone furoate/formoterol fumarate (MF/F) fixed-dose combination formulation administered via a metered-dose inhaler was investigated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Methods: Two 52-week, multicenter, double-blind, placebo-controlled trials with identical study designs were conducted in current or ex-smokers (aged =40 years), and pooled study results are presented herein. Subjects (n = 2251) were randomized to 26 weeks of twice-daily treatment with MF/F 400/10 µg, MF/F 200/10 µg, MF 400 µg, F 10 µg, or placebo. After the 26-week treatment period, placebo subjects completed the trial and 75% of subjects on active treatment entered a 26-week safety extension. Coprimary efficacy variables were mean changes in forced expiratory volume in one second (FEV1), area under the curve from 0 to 12 hours postdose (AUC0–12 h), and morning predose/trough FEV1 from baseline to the week 13 endpoint. Key secondary efficacy variables were St George’s Respiratory Questionnaire scores, symptom-free nights, time-to-first exacerbation, and partly stable COPD at the week 26 endpoint. Results: In the 26-week treatment period, significantly greater increases in FEV1 AUC0–12 h occurred with MF/F 400/10 versus MF 400 and placebo at the week 13 and week 26 endpoints (P = 0.032). These increases were over three-fold greater with MF/F 400/10 than with MF 400. Also, significantly greater increases in morning predose/trough FEV1 occurred with MF/F 400/10 versus F 10 and placebo at the week 13 endpoint (P \u3c 0.05). The increase was four-fold greater with MF/F 400/10 than with F 10. All active treatment groups achieved minimum clinically important differences from baseline (\u3e4 units) in St George’s Respiratory Questionnaire scores at week 26. Symptom-free nights increased by =14% in the MF/F 400/10, MF 400, and F 10 groups (P= 0.033 versus placebo). The incidence of exacerbations was lower in the MF/F groups (=33.3%) than it was in the MF, formoterol, and placebo groups (=33.8%) over the 26-week treatment period. The incidence of adverse events was similar in the active-treated and placebo-treated subjects across 26 weeks of treatment. Over the 1-year study period, there were no notable differences in the incidence or types of adverse events between the MF/F 400/10 and MF/F 200/10 groups compared with the MF or formoterol groups. Differences in rates of individual treatment-emergent adverse events were Conclusion: Patients treated with MF/F demonstrated significant improvements in lung function, health status, and exacerbation rates. Although significant improvements were seen with both doses, a trend showing a dose-response effect was observed in the lung function measurements

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD

RATIONALE: The purpose of this study was to investigate the clinical efficacy and safety of a fixed-dose combination of mometasone furoate/formoterol fumarate (MF/F) administered via a metered-dose inhaler in subjects with moderate-to-very severe chronic obstructive pulmonary disease (COPD). METHODS: This multicenter, double-blind, placebo-controlled trial had a 26-week treatment period and a 26-week safety extension. Subjects (n = 1196), at least 40 years old, were current or ex-smokers randomized to twice-daily inhaled MF/F 400/10 μg, MF/F 200/10 μg, MF 400 μg, F 10 μg, or placebo. The trial\u27s co-primary endpoints were mean changes from baseline, as area under the curve (AUC), in forced expiratory volume (FEV1) over 0-12 hours (AUC0-12 h FEV1) with MF/F versus MF, and in morning (AM) pre-dose (trough) FEV1 with MF/F versus F after 13 weeks of treatment. Key secondary endpoints were the effects of MF/F on respiratory health status using the Saint George\u27s Respiratory Questionnaire (SGRQ), symptom-free nights, partly stable COPD at 26 weeks, and time to first COPD exacerbation. RESULTS: The largest improvements in AUC0-12 h FEV1 were observed with MF/F 400/10 μg and MF/F 200/10 μg. Serial spirometry results demonstrated that bronchodilator effects with MF/F occurred rapidly (within 5 minutes), persisted for 12 hours after dosing, and were sustained over the 26-week treatment period. Similar findings were observed for AM pre-dose FEV1, for which effects were further investigated, excluding subjects whose AM FEV1 data were incorrectly collected after 2 days from the last dose of study treatment. Improvements in SGRQ scores surpassed the minimum clinically important difference of more than four units with both MF/F treatments. At 26 weeks, no notable between-treatment differences in the occurrence and nature of adverse events (AEs) were reported. No unexpected AEs were observed. Overall, 90 subjects reported AEs considered to be treatment-related, the most common of which were lenticular opacities, dysphonia, and oral candidiasis. DISCUSSION: In conclusion, MF/F treatments improved lung function and respiratory health status, reduced exacerbations, and were well tolerated in subjects with moderate-to-very severe COPD

FPGA basierte, konfigurierbare OFDM Sender-Plattform für die Positionsbestimmung mittels TDoA

Für die Evaluierung von Algorithmen zur Positionsbestimmung nach dem Time Difference of Arrival – Verfahren wird eine frei konfigurierbare OFDM Sender-Plattform benötigt. Da die Berechnung in Echtzeit erfolgen soll, ist eine Implementierung in rekonfigurierbarer Hardware (FPGA) erforderlich. Das Manuskript gibt sowohl einen Überblick über die Hintergründe und die Architektur des Sendesystems, als auch einen tieferen Einblick in verschiedene Lösungsdetails